Eli Lilly Beats Q1 Expectations on GLP-1 Sales, Raises Full-Year Outlook

Eli Lilly surpassed market expectations in its first-quarter financial results, driven by strong sales growth in its GLP-1 class diabetes and weight loss drugs. Following this positive performance, the company revised its full-year 2024 financial outlook upward. The company's revenue exceeded analyst estimates, thanks to an unexpected surge in GLP-1 drug sales. Products such as Mounjaro for diabetes treatment and Zepbound for weight loss recorded significant growth during the quarter, reinforcing Eli Lilly's market leadership in this segment. Eli Lilly's management painted an optimistic picture after the strong quarterly results. The company expects similar performance in the remainder of the year, driven by increasing demand and operational efficiency. Consequently, revenue and profit targets for 2024 have been raised. Investors responded positively to Eli Lilly's strong performance, with the company's shares gaining value following the news. Analysts suggest that if growth in the GLP-1 market continues, Eli Lilly could achieve similar successes in the coming period. This is not investment advice.